Oxford Biomedica plc (LON:OXB)
London · Delayed Price · Currency is GBP · Price in GBX 651.00
-8.00 (-1.21%)
Mar 5, 2026, 11:43 AM GMT
Oxford Biomedica Market Cap
Oxford Biomedica has a market cap or net worth of 796.56 million as of March 5, 2026. Its market cap has increased by 100.44% in one year.
Market Cap
796.56M
Enterprise Value
848.10M
Revenue
151.21M
Ranking
n/a
PE Ratio
n/a
Stock Price
651.00
Market Cap Chart
Since September 22, 1997, Oxford Biomedica's market cap has increased from 17.39M to 796.56M, an increase of 4,479.56%. That is a compound annual growth rate of 14.38%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 4, 2026 | 796.56M | 7.10% |
| Dec 31, 2025 | 743.72M | 67.15% |
| Dec 31, 2024 | 444.94M | 108.92% |
| Dec 29, 2023 | 212.97M | -50.00% |
| Dec 30, 2022 | 425.96M | -59.79% |
| Dec 31, 2021 | 1.06B | 24.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genus | 1.95B |
| Oxford Nanopore Technologies | 1.29B |
| PureTech Health | 296.79M |
| Avacta Group | 295.25M |
| Scancell Holdings | 139.06M |
| 4basebio | 85.13M |
| Bioventix | 80.99M |
| Hemogenyx Pharmaceuticals | 71.16M |